Table 2 The clinical parameters of PD patients with and without pRBD
pRBD (RBDSQ-J ≥ 5) | Non-pRBD (RBDSQ-J < 5) | p value | |
|---|---|---|---|
n; (M/F) | 18; (9/9) | 59; (31/28) | 0.85 |
Age (yrs) | 71.4 ± 5.0 | 68.3 ± 9.8 | 0.34 |
Body mass index (kg/m2) | 22.8 ± 2.4 | 22.3 ± 2.8 | 0.72 |
Disease duration (yrs) | 7.8 ± 5.5 | 6.4 ± 6.1 | 0.20 |
Hoehn and Yahr stage | 2.7 ± 0.9 | 2.5 ± 0.8 | 0.49 |
UPDRS III | 24.5 ± 12.0 | 19.9 ± 13.0 | 0.16 |
UPDRS IV | 2.4 ± 2.4 | 1.6 ± 2.3 | 0.037 |
Motor complications, n (%) | 8 (44.4) | 19 (32.2) | 0.34 |
Wearing-off, n (%) | 5 (27.8) | 18 (30.5) | 1.0 |
Early morning dystonia, n (%) | 4 (22.2) | 0 (0.0) | 0.0023 |
Dyskinesia, n (%) | 5 (27.8) | 10 (16.9) | 0.32 |
PSQI global score | 5.6 ± 4.0 | 5.1 ± 3.4 | 0.76 |
PSQI component score | |||
Sleep quality | 1.1 ± 0.8 | 0.9 ± 0.6 | 0.38 |
Sleep latency | 0.9 ± 1.1 | 0.8 ± 0.9 | 0.54 |
Sleep duration | 0.5 ± 0.8 | 0.9 ± 0.9 | 0.05 |
Habitual sleep efficiency | 0.4 ± 0.7 | 0.5 ± 0.9 | 0.87 |
Sleep disturbances | 0.8 ± 0.6 | 0.8 ± 0.6 | 0.83 |
Use of sleeping medication | 0.9 ± 1.3 | 0.6 ± 1.1 | 0.14 |
Daytime dysfunction | 0.8 ± 1.0 | 0.6 ± 0.8 | 0.39 |
ESS | 7.3 ± 4.7 | 6.2 ± 4.5 | 0.34 |
PDSS-2 total score | 16.1 ± 7.4 | 12.1 ± 7.9 | 0.044 |
PDQ-39 summary index | 31.2 ± 24.4 | 23.8 ± 19.2 | 0.25 |
PDQ-39 domain score | |||
Mobility | 38.2 ± 35.8 | 33.9 ± 31.3 | 0.69 |
ADL | 36.1 ± 33.4 | 27.4 ± 27.2 | 0.39 |
Emotional well-being | 37.0 ± 27.2 | 22.4 ± 21.9 | 0.029 |
Stigma | 22.2 ± 19.1 | 19.1 ± 21.9 | 0.22 |
Social support | 12.0 ± 22.4 | 8.8 ± 16.6 | 0.44 |
Cognition | 31.6 ± 21.1 | 17.5 ± 18.9 | 0.0038 |
Communication | 19.4 ± 22.0 | 13.7 ± 18.2 | 0.27 |
Bodily discomfort | 28.2 ± 25.4 | 21.5 ± 24.0 | 0.33 |
BDI-II | 14.2 ± 9.1 | 11.6 ± 9.2 | 0.22 |
PFS | 2.7 ± 1.1 | 2.7 ± 1.1 | 0.78 |
Levodopa (mg/day) | 270.8 ± 135.6 | 315.7 ± 154.0 | 0.44 |
LED (mg/day) | 312.9 ± 234.7 | 372.5 ± 338.0 | 0.87 |